ITGR
Integer Holdings Corp
Healthcare • CIK: 0001114483
Loading...
Market Cap
$3.49B
P/E (TTM)
40.6x
Rev Growth (TTM)
+9.5%
Net Margin (TTM)
4.7%
FCF Yield (TTM)
3.5%
FCF Margin (TTM)
6.6%
Cash Flow Health
Free Cash Flow7/8 positive
TTM$121M
Q3 '25
$46M+86%
Q2 '25
$25M+310%
FCF Margin
TTM6.6%
Q3 '259.9%+90%
Sector: 0.0%Above Avg
OCF Margin11.1%
OCF/NI2.35x
CapEx Coverage2.5x
FCF Yield3.5%
FCF Growth (2Y)+48%
Cash Conversion Cycle
95 days
DSO: 55+DIO: 71−DPO: 30
Capital Allocation & Returns
Total Shareholder Yield
TTM0.0%
Div Yield0.0%
Insufficient data
Dividend & Payout Metrics
Dividend Yield (TTM)0.0%
Free Cash Flow (TTM)$121.3M
Capital Return / FCF0.0%
Est. Dividends Paid (TTM)$0
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
5.9%
Stable
+0.0% YoY+3.0%
P25MedianP75
75th pctl (med: 0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
9.0%
8Q: 10.3%
Asset Turnover
0.56x
8Q: 0.55x
Leverage (1+D/E)
1.68x
D/E: 0.68x
DuPont: 8.5% ≈ 5.9% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
10.43x
8Q:–
Invested Cap Turn
0.69x
8Q:0.62x
+14.8%
CapEx Intensity
3.1%
8Q:3.7%
CapEx/Depreciation
0.67x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $1.8B | $467.7M↓1.8% | $476.5M↑8.9% | $437.4M↓2.7% | $449.5M↑4.2% | $431.4M↑0.8% | $427.9M↑4.9% | $407.8M↑0.8% | $404.5M |
Operating Income | $222.4M | $56.4M↓4.9% | $59.3M↑19.7% | $49.6M↓13.1% | $57.0M↓1.7% | $58.0M↑6.5% | $54.5M↑40.8% | $38.7M↓11.1% | $43.5M |
Net Income | $86.9M | $39.7M↑7.2% | $37.0M↑264.6% | $-22.5M↓168.8% | $32.7M↓7.7% | $35.4M↑13.4% | $31.2M↑52.4% | $20.5M↓22.2% | $26.4M |
Operating Cash Flow | $204.0M | $65.6M↑49.5% | $43.9M↑40.2% | $31.3M↓50.5% | $63.2M↓11.6% | $71.5M↑51.4% | $47.2M↑103.3% | $23.2M↓58.2% | $55.6M |
Free Cash Flow | $121.3M | $46.3M↑86.1% | $24.9M↑310.4% | $6.1M↓86.3% | $44.1M↓3.0% | $45.5M↑183.3% | $16.1M↑375.2% | $-5.8M↓131.5% | $18.5M |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
40.6x
Volatile
8Q: 122.2x-12632%
High PEG ratio (4.3x) suggests expensive for growth
Valuation Lenses
Earnings
40.6x
vs – sector
Cash Flow
43.5x
EV/FCF vs –
Growth-Adj
4.3xPEG
Expensive for growth
Quality-Adj
6.9P/E per %ROIC
ROIC: 5.9%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$3.49B
EV–
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
68/100
High Quality
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Above Avg
5.3%
8Q:–
Return on Invested Capital (ROIC)Top 25%
5.9%
8Q:–
+3.0%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 9.0%
Asset Turnover: 0.56x
Earnings Quality
Cash Conversion
2.35x
OCF / Net Income ✓
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin26.9%
Capital Efficiency
Invested Capital Turnover0.69x
Working Capital
Cash Conversion Cycle95 days
Growth Quality & Momentum
Moderate Growth
Growth Quality Score
70/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
9.5%
OpInc Growth YoY
-2.7%
EPS Growth YoY
-26.2%
FCF 3Y CAGR
48.3%
Growth Quality Analysis
✓Efficient Growth: Free cash flow growing faster than revenue
Margin Quality & Sustainability
Low Quality
Profitability Cascade
Gross
26.9%
Operating
12.1%
Above Avg in sector
Net
4.7%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
+1.9 pts
FCF: 6.6% | Net: 4.7%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Adequate
Net Debt / EBITDA
–Net Debt: $1.13B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.68x
Balance sheet risk & solvency analysis